Navigation Links
Pharmacopeia Announces Third Quarter 2007 Financial Results
Date:11/1/2007

ut are not limited to, statements about the successful implementation of Pharmacopeia's strategic plans, Pharmacopeia's plans to develop PS433540, a product candidate from its DARA program, Pharmacopeia's Phase 2 and Phase 1 clinical studies with respect to PS433540, including timing and expected outcomes of such studies, Pharmacopeia's plans to develop PS178990, a product candidate from its SARM program, Pharmacopeia's Phase 1 clinical studies with respect to PS178990, including timing and expected outcomes of such studies, Pharmacopeia's estimates of the market opportunities for its product candidates, including PS433540 and PS178990, Pharmacopeia's ability to successfully perform under its collaborations with Bristol-Myers Squibb, Cephalon, GlaxoSmithKline, Organon and Wyeth, Pharmacopeia's ability to build its pipeline of novel drug candidates through its own internally-funded drug discovery programs, third party collaborations and in-licensing, Pharmacopeia's ability to raise additional capital, Pharmacopeia's expectations concerning the development priorities of its collaborators, their ability to successfully develop compounds and its receipt of milestones and royalties from the collaborations, Pharmacopeia's anticipated operating results, financial condition, liquidity and capital resources, Pharmacopeia's expectations concerning the legal protections afforded by U.S. and international patent law, Pharmacopeia's ability to pursue the development of new compounds and other business matters without infringing the patent rights of others, additional competition, and changes in economic conditions.

Further information about these and other relevant risks and uncertainties may be found in Pharmacopeia's Reports on Form 8-K, 10-Q and 10-K filed with the U.S. Securities and Exchange Commission. Pharmacopeia urges you to carefully review and consider the disclosures found in its filings which are available in the SEC EDGAR database at

SOURCE Pharmacopeia
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Pharmacopeia Announces Positive Results from Initial DARA Clinical Trial
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Sygnis Pharma AG announces date for presentation of clinical results
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... N.H. , March 2, 2015 /PRNewswire/ ... provider of professional-grade vitamins, supplements, prescription products ... announced a strategic partnership with Anabolic Laboratories, ... for healthcare professionals. This new partnership will ... into new licensed healthcare practitioner segments and ...
(Date:3/2/2015)... March 2, 2015  BC Technical, the nation,s ... acquired Eclipse Systems, a Nuclear Imaging service company ... part of their ongoing vision to provide the ... rate, BC Technical continues to expand their reach ... to add valuable resources and knowledge in addition ...
(Date:3/2/2015)... Corporation (NYSE: XON ), a leader ... and full year results for 2014.  ... Acquired ActoGeniX, a European clinical stage biopharmaceutical company ... other innovative products.  Its proprietary TopAct™ platform enables ... lactis ) to generate biologically-contained ActoBiotics™ for in ...
Breaking Medicine Technology:Anabolic Laboratories Selects Emerson Ecologics As Distribution Partner 2Anabolic Laboratories Selects Emerson Ecologics As Distribution Partner 3BC Technical Acquires Eclipse Systems 2Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 2Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 3Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 4Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 5Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 6Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 7Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 8Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 9Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 10Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 11Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 12Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 13Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 14Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 15Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 16Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 17Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 18Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 19Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 20Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 21Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 22Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 23Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 24
... Calif., Nov. 19 WaferGen Biosystems, Inc. (OTC ... genetic analysis systems, today announced a new, innovative ... using the SmartChip(TM) Real-Time PCR System. By ... WaferGen will offer universities, pharmaceutical and diagnostic companies ...
... , SAN DIEGO, Nov. 19 ... first point-of-care method for measuring platelet reactivity, announces that ... methods evaluated in the POPular study, which was presented ... American Heart Association,s annual Scientific Sessions. The VerifyNow P2Y12 ...
Cached Medicine Technology:WaferGen to Introduce New Service for Gene-Expression Profiling Using the SmartChip(TM) Real-Time PCR System 2WaferGen to Introduce New Service for Gene-Expression Profiling Using the SmartChip(TM) Real-Time PCR System 3WaferGen to Introduce New Service for Gene-Expression Profiling Using the SmartChip(TM) Real-Time PCR System 4VerifyNow(R) System Highlighted in POPular Study Comparing Platelet Reactivity Tests 2
(Date:3/3/2015)... 2015 HealthCarePoint (HCP) , ... announced today that it has completed development of ... Interchange Standards Consortium (CDISC). HCP will continue to ... knowledge-based training and certifications globally. HCP’s in-kind services ... support as well as development of dynamic identification ...
(Date:3/3/2015)... 03, 2015 Aureus Medical Group (web: ... jobs, has announced that it will participate as an ... Tuesday, March 17, 2015 in St. Louis, MO. , ... meet job-seeking residents and fellows in a comfortable, relaxed ... will be available to speak with attendees about ...
(Date:3/3/2015)... Join colleagues from across the continent at ... The Learning Summit is a working retreat for community ... explore strategies for focusing entire colleges on improving and ... at the Community College Research Center, Teachers College, Columbia ... Monday through Wednesday, the program will devote a half-day ...
(Date:3/2/2015)... Getting customers to discover a whole new world in ... the 31st annual Frozen Food Month kicks off. The ... Foods Association (NFRA) to stimulate the awareness and options ... frozen selections and is thrilled to be part of ... crafted with simple ingredients, no preservatives or artificial ingredients. ...
(Date:3/2/2015)... Dr. David Knepp, a leading chiropractor ... Doctors on Liens to bring his medical ... for personal injury victims to have access to multiple ... lien basis. However, San Diego Chiropractic Group ... M.D., pain management physician, massage, and acupuncture to help ...
Breaking Medicine News(10 mins):Health News:HealthCarePoint Completes CDISC BlueCloud Transnational Commerce Through In-kind Donations 2Health News:HealthCarePoint Completes CDISC BlueCloud Transnational Commerce Through In-kind Donations 3Health News:Register Today for the League for Innovation in the Community College’s Learning Summit 2015 2Health News:Take a Fresh Look at Frozen with Ian’s 2Health News:Distinguished Doctor Brings His Multi-Specialty Medical Group to Doctors on Liens in San Diego 2
... the University of Pennsylvania School of Medicine in,Philadelphia, USA, has ... day have,impaired mental ability much similar to those who go ... was published in the March issue of the,journal Sleep involved ... hours a night for two weeks, the second group slept ...
... of Neurology, London has shown that,there are several preliminaries ... with migraine attacks that identification of these symptoms,would give ... it better.// ,The group of 97 participants were ... attack on a daily basis for three months. The ...
... rules that would help improve patient safety by reducing medication ... as many as 7,000 deaths. These errors have been attributed ... doctors on prescriptions, or too many new drugs for doctors ... 1999 study reported// between 45,000 and 98,000 death due to ...
... Stargardt's macular degeneration, also called juvenile macular degeneration, is ... people. This condition results from a defect in the ... protein that removes all-trans-retinaldehyde, a vision byproduct, from retinal ... retinal-pigmented epithelium (RPE), a layer of cells near the ...
... Health and Nutrition Examination Survey has now uncovered a ... is a form of gum disease that causes infection ... teeth. The participants of the study where divided into ... from the teeth, an indicator of the presence of ...
... heart beat, during recovery after exercise has been found ... increased risk of death and one that occurs during ... with no history of heart failure, valve disease or ... see if frequent ventricular ectopy occurred and when it ...
Cached Medicine News:
CTAD tubes contain theophylline, adenosine and dipyridamol. Coagulation and DTAD tubes are for examination of coagulation parameters....
... Coagulation tubes contain a ... is available with a citrate ... or 0.129 mol/l (3.8%). The ... citrate solution to 9 parts ...
Inquire...
Inquire...
Medicine Products: